Quadrature Capital Ltd bought a new position in Mesa Laboratories, Inc. (NASDAQ:MLAB – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,700 shares of the medical instruments supplier’s stock, valued at approximately $221,000.
A number of other large investors have also made changes to their positions in the company. Canada Pension Plan Investment Board purchased a new position in shares of Mesa Laboratories in the 2nd quarter worth $26,000. FMR LLC grew its position in Mesa Laboratories by 34.1% in the third quarter. FMR LLC now owns 393 shares of the medical instruments supplier’s stock worth $51,000 after acquiring an additional 100 shares in the last quarter. Quantbot Technologies LP bought a new stake in Mesa Laboratories during the third quarter worth approximately $70,000. Berry Wealth Group LP purchased a new stake in Mesa Laboratories during the third quarter valued at approximately $204,000. Finally, Amalgamated Bank lifted its stake in shares of Mesa Laboratories by 6.5% in the 3rd quarter. Amalgamated Bank now owns 1,588 shares of the medical instruments supplier’s stock valued at $206,000 after purchasing an additional 97 shares during the last quarter. 90.60% of the stock is currently owned by institutional investors.
Mesa Laboratories Stock Performance
Shares of Mesa Laboratories stock opened at $128.86 on Wednesday. Mesa Laboratories, Inc. has a 52 week low of $83.68 and a 52 week high of $141.17. The company has a market capitalization of $699.71 million, a PE ratio of -2.83 and a beta of 0.86. The stock’s fifty day moving average is $120.06 and its two-hundred day moving average is $114.90. The company has a quick ratio of 0.51, a current ratio of 0.70 and a debt-to-equity ratio of 0.65.
Mesa Laboratories Announces Dividend
Analyst Upgrades and Downgrades
Several research firms recently weighed in on MLAB. StockNews.com lowered Mesa Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, November 13th. Wells Fargo & Company started coverage on shares of Mesa Laboratories in a report on Tuesday, August 27th. They issued an “underweight” rating and a $120.00 target price for the company. Finally, Evercore ISI upped their price target on shares of Mesa Laboratories from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st.
Check Out Our Latest Stock Analysis on Mesa Laboratories
Insider Buying and Selling at Mesa Laboratories
In other news, CEO Gary M. Owens sold 2,518 shares of the business’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $113.62, for a total value of $286,095.16. Following the completion of the sale, the chief executive officer now owns 45,888 shares in the company, valued at approximately $5,213,794.56. The trade was a 5.20 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Brian David Archbold sold 1,499 shares of Mesa Laboratories stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $125.00, for a total transaction of $187,375.00. The disclosure for this sale can be found here. 4.40% of the stock is owned by corporate insiders.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
Featured Stories
- Five stocks we like better than Mesa Laboratories
- What is a Stock Market Index and How Do You Use Them?
- Survey Reveals: Which States Saw the Biggest Investment Gains in 2024?
- How to Invest in Insurance Companies: A Guide
- Amazon’s Healthcare Gamble: A New Era of Medical Disruption
- How to Start Investing in Real Estate
- Semiconductor Giant Synopsys Slides 14% — Time to Take Notice
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.